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We evaluated circulating aminoterminal and carboxy-
terminal propeptides of type I procollagen  and total al-
kaline phosphatase levels in eighty consecutive pa-
tients affected by Paget’s disease of bone. We
compared the biochemical data with the extent of
bone disease calculated on the basis of the bone scin-
tigraphic indices. 
Serum aminoterminal propeptide of type I procol-
lagen levels were high in 77% of patients, serum car-
boxyterminal propeptide of type I procollagen levels in
22% and serum total alkaline phosphatase levels in
76%. We found significant correlations between the
three markers studied. The three biochemical markers
correlated significantly with the bone scintigraphic ac-
tivity indices, but the highest correlation coefficient
was between the aminoterminal propeptide and total
alkaline phosphatase. 
We conclude that there is a discrepancy between
serum levels of the propeptides studied in relation to
Paget’s disease of bone. The sensitivity of the carboxy-
terminal propeptide of type I procollagen in this dis-
ease is low. In contrast the aminoterminal propeptide
may be as sensitive a marker for the evaluation of this
disorder as total alkaline phosphatase, and in addition
may be more specific. 
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Introduction
The carboxyterminal propeptides of type I procollagen
(PICP) and the aminoterminal propeptides of type I pro-
collagen (PINP) arise from the cleavage of a large pre-
cursor of type I collagen by two specific proteolytic en-
zymes (1). These two peptides have different molecular
weights and are delivered into the circulation in a 1/1
molar ratio. They are rapidly cleared from the blood by
different receptors via endocytosis in the liver (2,3).
Their values may be considered as indices of the rate of
synthesis of type I collagen, the major protein in the or-
ganic matrix of bone.
Paget’s disease of bone is a metabolic bone disor-
der, characterized by increased bone turnover (4). Tra-
ditionally total alkaline phosphatase (TAP) and urinary
hydroxyproline, considered markers of bone forma-
tion and resorption respectively, have been used as in-
dices of bone activity in the study of this disorder (5).
Other biochemical markers of bone metabolism have
been studied  and have presented varying diagnostic
sensitivity. Serum concentrations of the PICP and PINP
may be more specific markers of bone turnover than
TAP. Nevertheless, the sensitivity of the PICP in Paget’s
disease of bone has been reported to be relatively low
(6).
Recently, a method for measuring  serum concentra-
tions of the intact trimeric form of circulating PINP has
become commercially available (7).
The aim of the present study is to compare serum
concentrations of PICP and PINP in a group of patients
with Paget’s disease of bone. We analyse the correla-




Eighty consecutive patients (50 males and 30 females, mean
age 69 years, range 46–88 years) affected by Paget’s disease of
bone, were included in a cross sectional prospective study.
Paget’s disease was  diagnosed by radiography and bone scan
with 99m-Technetium. The mean duration of disease was 85.8
± 65.5 months since diagnosis. Disease activity was evaluated
by three methods:
1. The condition was considered polyostotic when 2 or more
bones were affected, and monostotic when only a single
bone was involved.
2. Sites affected were divided into four categories: pelvis,
head, axial skeleton and limbs. The patients were classified
according to the number of regions affected (one, two,three
or four) (8).
3. Scintigraphic indices of disease activity:
The scintigraphic disease activity index (AI) in all patients
was calculated using the following calculation:
AI= bone extent 3 uptake coefficient 
for all the  bones affected.
The extent of the disease was measured using the coeffi-
cient given by Coutris et al. (9). The scintigraphic uptake coef-
ficient was obtained for each bone on a 6-point scale (10). The
scintigraphic index of disease activity for each patient was ob-
tained as the sum of the indices of activity for the affected
bones.
Blood samples were obtained from each patient between
8:00 a.m. and 10:00 a.m. Serum samples were kept frozen at
– 80 °C until analysis. We measured TAP, PINP and PICP.
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Analytical methods
Serum concentrations of TAP  were routinely determined on a
BM/Hitachi 717 analyser using Boehringer Mannheim kits. In-
ter-assay coefficent of variation (CV) was 5 %.
Serum PINP and PICP were assayed by radioimmunoassay
(Orion Diagnostica, Finland). Intra-assay CVs were 11 % and
10.8 % respectively.
Statistical analysis
Between-group comparisons were done by the Mann-Whit-
ney test. The correlation coefficients were obtained from the
non-parametric Spearman’s rank test. As regards affected




The disease was polyostotic in fifty patients (62.5 %)
and monostotic in thirty patients (37.5 %). As regards
the number of regions affected, 40 % of patients pre-
sented with one site affected, 32.5 % with two, 20 %
with three and 7.5 % with four. 
Bone scintigraphic index 
Values for the activity index ranged from 1.2 to 220.
Monostotic patients had lower values than  polyostotic
(17.49 ± 11.55 vs. 52.94 ± 41.5, p < 0.001).
Biochemical markers
Serum TAP levels were high in 61 patients (76 %). Serum
concentrations of PICP were increased in 18 patients
(22 %). Serum concentrations of PINP were high in 62
patients (77 %). Table 1 shows mean absolute values of
the three bone markers studied, and the bone scinti-
graphic index in monostotic and polyostotic patients. 
In patients with polyostotic disease significantly
higher values were found for TAP (p = 0.006) and PINP
(p = 0.001), but not for the PICP (p = 0.06). All data are
shown in figure 1.
If we separate the patients by specific areas of in-
volvement significant differences appear between all
the groups as regards serum TAP (p = 0.001) and
serum PINP (p = 0.001) but not for levels of serum PICP
(p = 0.06). Results are shown in table 2.
Correlation study
The three biochemical markers studied were signifi-
cantly correlated with the bone scintigraphic indices,
but serum TAP and serum PINP showed the highest
correlation coefficients (r = 0.63, p < 0.001 and r = 0.60,
p < 0.001, respectively). The correlation coefficient
between PICP and the scintigraphic indices was
r = 0.28, p = 0.01. 
We observed significant correlations between PINP
and TAP (r = 0.80, p < 0.001), PICP and TAP (r = 0.37,
p = 0.001), and PINP and PICP (r = 0.52, p < 0.001).
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Tab. 1 Biochemical markers of bone turnover and scinti-
graphic index in patients with monostotic and polyostotic
Paget’s disease of bone.
Monostotic Polyostotic Normal
(n=30) (n=50) range
AI 17.5 ± 11.5 52.9 ± 41.5
TAP mkat/l 3.8 ± 2.9 8.9 ± 11.6 0.6-2.1
PINP mg/l 80.7 ± 224.3 382.4 ± 385.5 19-84
PICP mg/l 144.0 ± 36.8 261.6 ± 309 38-202
Values are mean ± SD. AI = Bone scintigraphic index. 
TAP = total alkaline phosphatase; PINP = aminoterminal pro-
peptide of type I procollagen; PICP = carboxyterminal propep-
tide of type I procollagen.
Fig. 1 Individual levels of serum propeptide carboxyterminal
of type I procollagen, propeptide aminoterminal of type I pro-
collagen and total alkaline phosphatase in polyostotic and
monostotic patients. Areas between horizontal lines represent
normal ranges.
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Discussion
Total alkaline phosphatase, PINP and PICP are consid-
ered to be biochemical markers of bone formation (11).
Alkaline phosphatase is a marker of enzyme activity of
osteoblasts. The propeptides are released by osteo-
blasts during bone formation. Although type I collagen
is found in other tissues, the rate of turnover for these
tissues is lower than that for bone. Total alkaline phos-
phatase is still the most widely used bone marker in the
clinical setting but it is also produced in other tissues
(12).
In the present study the three markers of bone for-
mation studied correlated with the activity and extent
of the disease; however they present a number of dif-
ferences.
Serum alkaline phosphatase and PINP show a simi-
lar proportion of high values in the Paget’s patients. In
contrast, concentrations of serum PICP were in the nor-
mal range in both  monostotic and polyostotic patients.
On separating patients by specific areas of involve-
ment we found significant differences between each
group for TAP and PINP values but not for PICP. These
results, similar to data reported previously (13), show
that serum PICP is relatively insensitive as a marker of
activity in Paget’s disease of bone.
This discrepancy between values of serum PICP and
PINP in active Paget’s disease may be due to differ-
ences in the clearance of the propeptides from the cir-
culation, or to the existence of different circulating
forms of type I procollagen (14). 
The significant correlations between the biochemi-
cal markers studied and the scintigraphic indices show
the usefulness of both determinations for assessing
Paget’s disease activity.
We conclude that the sensitivity of PINP as a marker
of activity in the study of patients with Paget’s disease
of bone is comparable to that of TAP. It may also be a
more specific marker of bone turnover directly related
to collagen synthesis.
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Tab. 2 Biochemical markers of bone turnover according to
the number of regions affected.
Bone marker Number of regions affected
1   2   3                   4
(n=32)         (n=26)         (n=16)       (n=6)
TAP mkat/l 3.7±2.8 7.5±11.5 8.2±7.5      19.0±18.5 
PINP mg/l 187.0±222.8 296.8±326   344.0±306 889.5±524
PICP mg/l 139.5±35.3 218.8±210   293.9±349 424.5±538   
Values are mean ± SD. Definitions are in Table 1.
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